CTOs on the Move

Gaia Herbs

www.gaiaherbs.com

 
Gaia Herbs has established itself as the leading grower and producer of Certified Organic (COG) herbs and herbal products. Gaia Herbs strives to produce pure plant medicines of exceptional quality and purity while enriching the ecology of the earth and the health and harmony of the people that use our phyto-medicines. Gaia Herbs is a certified organic grower and nationally-branded manufacturer of liquid herbal extracts based in Western NC. Find our products at health food retailers and co-ops, natural products retail chains, and healthcare professionals. Our commitment to certified organic herbs ensures strength, purity, and efficacy of our herbal products.
  • Number of Employees: 25-100
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Funding

Gaia Herbs raised $20.9M on 02/10/2016
Gaia Herbs raised $10M on 02/14/2019

Similar Companies

US Micron

US Micron is a Lenexa, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Meadow Lane Pharmacy

Meadow Lane Pharmacy is a Lincoln, NE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OnSite Waste Technologies

Save time, money and resources with the smarter, simpler, and safer way to handle regulated medical waste

Bayless Integrated Healthcare

Bayless Healthcare offers a progressive approach to Integrated Healthcare in the Phoenix area. Services include primary care, behavioral health & counseling services & wellness programs.

Zentaris

Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company`s lead product, Macrilen™ (macimorelin), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macrilen™ is currently marketed in the United States through a license agreement with Novo Nordisk and Aeterna Zentaris receives double-digit royalties on sales. Aeterna Zentaris owns all rights to macimorelin outside of the U.S. and Canada. Aeterna Zentaris is also leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of child-onset growth hormone deficiency (CGHD), an area of significant unmet need. The Company is actively pursuing business development opportunities for the commercialization of macimorelin in Europe and the rest of the world, in addition to other non-strategic assets to monetize their value.